Abstract:NAC1 is a nuclear factor belonging to the BTB gene family. The BTB domain of NAC1 is responsible for its homodimerization and interaction with other proteins to form a complex that plays an important role in maintaining the pluripotency of ES cells and in the development of chemoresistance in ovarian cancer cells. Elucidating the molecular mechanisms underlying how NAC1 contributes to drug resistance is fundamental to improve clinical outcome in recurrent postchemotherapy ovarian cancer patients. The purpose of this study was to determine whether autophagy, a conserved response to several types of stresses including therapeutic stress, was involved in NAC1-mediated resistance to cisplatin, a commonly used chemotherapeutic drug in the treatment of ovarian cancer. We found that treatment with cisplatin caused a robust activation of autophagy in NAC1-expressing ovarian cancer cell lines including A2780, OVCAR3, and SKOV3, based on the alteration of LC3-II and p62 by Western blot analysis, and the presence of GFP-LC3 puncta by microscopic observation. We further demonstrated that knockdown of NAC1 expression by RNA interference or inactivation of NAC1 by inducing the expression of NAC1 deletion mutant that contains only the BTB domain significantly inhibited the cisplatin-induced autophagy, resulting in increased cisplatin cytotoxicity as measured by MTT viability assay. Moreover, we observed that inhibition of autophagy and sensitization to cisplatin by NAC1 knockdown or inactivation were accompanied by induction of apoptosis, as evidenced by increases in Annexing V staining and in the levels of proapoptotic proteins caspase-3 and PARP. To confirm that the sensitizing effect of NAC1 inhibition on the cytotoxicity of cisplatin was mediated through suppression of autophagy, we assessed the effects of autophagy inhibitors, 3-MA and chloroquine, on the cytotoxicity of cisplatin. Treatment of cancer cells with 3-MA and chloroquine also enhanced the sensitivity of SKOV3, A2780, and OVCAR3 cells to cisplatin, indicating that suppression of autophagic response indeed renders the NAC1-expressing ovarian cancer cells more sensitive to cisplatin. The regulation of autophagy by NAC1 appeared to be mediated via HMGB1 (high-mobility group box 1), as NAC1 could regulate the expression, translocation and release of HMGB1, which is known to activate autophagy by disrupting the interaction between beclin 1 and bcl-2. The results of our study not only revealed a new mechanism governing cisplatin sensitivity but also identified NAC1 as a novel regulator of autophagy. Thus, the NAC1-mediated autophagy may be exploited as a new target for enhancing the efficacy of cisplatin against ovarian cancer or other types of malignancies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the Second AACR International Conference on Frontiers in Basic Cancer Research; 2011 Sep 14-18; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2011;71(18 Suppl):Abstract nr C63.

Nucleus accumbens-1/GADD45GIP1 axis mediates cisplatin resistance through cellular senescence in ovarian cancer

NAC1 Modulates Sensitivity of Ovarian Cancer Cells to Cisplatin by Altering the HMGB1-mediated Autophagic Response

GANT61 Elevates Chemosensitivity to Cisplatin Through Regulating the Hedgehog, AMPK and Camp Pathways in Ovarian Cancer

Abstract C63: Identification of NAC1 as a novel regulator of autophagy: Its implication in cisplatin resistance

Nucleosome Assembly Protein 1-Like 3 Enhances Cisplatin Resistance of Ovarian Cancer Cell by Activating Transforming Growth Factor-Beta Pathway.

The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer

PGC1α regulates mitochondrial oxidative phosphorylation involved in cisplatin resistance in ovarian cancer cells via nucleo-mitochondrial transcriptional feedback

Npgc1α PROMOTES CISPLATIN RESISTANCE IN HUMAN OVARIAN CARCINOMA CELLS THROUGH UPREGULATION OF MITOCHONDRIA BIOGENESIS

PGC1α promotes cisplatin resistance in human ovarian carcinoma cells through upregulation of mitochondrial biogenesis

The Nrf2/PGC1α Pathway Regulates Antioxidant and Proteasomal Activity to Alter Cisplatin Sensitivity in Ovarian Cancer

GADD45α alleviates the CDDP resistance of SK-OV3/cddp cells via redox-mediated DNA damage

Mitochondrial dysfunction decreases cisplatin sensitivity in gastric cancer cells through upregulation of integrated stress response and mitokine GDF15

PGC1 Promotes Cisplatin Resistance in Ovarian Cancer by Regulating the HSP70/HK2/VDAC1 Signaling Pathway

ACY1-mediated deacetylation of GSTP1 at lysine 30 suppresses cisplatin resistance in epithelial ovarian cancer

PGC1α Promotes Cisplatin Resistance in Ovarian Cancer by Regulating the HSP70/HK2/VDAC1 Signaling Pathway

Mechanistic Insights of NAC1 Nuclear Export and Its Role in Ovarian Cancer Resistance to Docetaxel

Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells

Investigating the potential role of α-SNAP in preventing chemotherapy-induced ovarian dysfunction: Insights from cellular and animal models

Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy

Down-regulation of Ras-related Protein Rab 5C-Dependent Endocytosis and Glycolysis in Cisplatin-resistant Ovarian Cancer Cell Lines

LncRNA NNT-AS1 contributes to the cisplatin resistance of cervical cancer through NNT-AS1/miR-186/HMGB1 axis